David Jorden
Chief Executive Officer at NUO THERAPEUTICS, INC.
Net worth: 2 M $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| James Gorman | M | 65 | 18 years | |
| Peter Clausen | M | 58 | 16 years | |
| Eric Grossman | M | 57 | 18 years | |
| Frederick Pollock | M | 44 | 18 years | |
| Scott Pittman | M | 65 | 8 years | |
| Jon Alexander Schwartz | M | - |
Nanospectra Biosciences, Inc.
 Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | 19 years |
| C. Winzer | M | 67 | 15 years | |
| Gary Balkema | M | 69 | 8 years | |
| Paul Mintz | M | 75 | 7 years | |
| Bob Casale | M | 65 | 8 years | |
| Pat Pace | M | 52 |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | 14 years |
| Brian A. Pryor | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | - |
| Glenn P. Goodrich | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | 19 years |
| James Howland | M | - | 16 years | |
| L. Blair Shamel | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | - |
| Bradley Nyberg | M | - |
Nanospectra Biosciences, Inc.
Nanospectra Biosciences, Inc. Pharmaceuticals: MajorHealth Technology Nanospectra Biosciences, Inc. provides commercializing particle-based therapies the selective and precise thermal destruction of solid tumors. It develops AuroLase Therapy utilizing AuroShell Particles (also referred to as nanoshells) for the precise, particle-based thermal ablation of solid tumors. The company was founded by Naomi J. Halas, Jennifer L. West, and Daniel M. Watkins in 2002 and is headquartered in Houston, TX. | - |
| Taylor Henricks | M | - | 17 years | |
| Kathy Bergsteinsson | F | - | 19 years | |
| David Cook | M | - | 20 years | |
| Frank Ducomble | M | - | 18 years | |
| Jonathan Sessler | M | 68 |
The University of Texas at Austin
| 40 years |
| Mandell Crawley | M | 48 | 20 years | |
| Jonathan Starbecker | M | - | 18 years |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Dean E. Tozer | M | 57 | 2 years | |
| Jonathan Pruzan | M | 55 | 18 years | |
| Steven Shallcross | M | 62 | 2 years | |
| Thomas R. Nides | M | 63 | 5 years | |
| Joe A. Del Guercio | M | 52 | 5 years | |
| Natasha Giordano | F | 62 | 7 years | |
| James S. Benson | M | 84 | 9 years | |
| Andrew Scott Maslan | M | 54 | 8 years | |
| Robert Scott | M | 78 | 2 years | |
| Martin P. Rosendale | M | 66 | 7 years | |
| Craig B. Mendelsohn | M | 69 | 3 years | |
| Donald E. Moss | M | 79 |
The University of Texas at Austin
| 6 years |
| Nadav Zohar | M | 59 | 7 years | |
| Mayree Clark | F | 67 | 24 years | |
| Carelyn P. Fylling | F | 76 | 17 years | |
| Lawrence S. Atinsky | M | 55 | 4 years | |
| Buddie Cloys Ballard | M | - |
The University of Texas at Austin
| 4 years |
| John W. Hadden | M | 54 | 7 years | |
| Jaye L. Thompson | M | 58 |
Opexa Therapeutics, Inc.
 Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 4 years |
| Thomas Kelleher | M | 67 | 15 years | |
| Ruth Porat | F | 66 | 12 years | |
| Donald Healey | M | 62 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 7 years |
| Randall W. Poston | M | - |
The University of Texas at Austin
| 5 years |
| Stacy L. Brainin | F | - |
The University of Texas at Austin
| 7 years |
| Vladislav Poshmorga | M | - | 4 years | |
| Todd Taylor | M | - | 8 years | |
| John Ghiselli | M | 60 |
The University of Texas at Austin
| 6 years |
| Todd Schwarzinger | M | - | 9 years | |
| Sean Willett | M | - | - | |
| Thomas J. Murphy | M | - |
The University of Texas at Austin
| 5 years |
| Laura A. Einspanier | F | - |
The University of Texas at Austin
| 8 years |
| Allen H. Kupetz | M | - |
The University of Texas at Austin
| 3 years |
| Kenny S. Frazier | M | - |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | - |
| Dame Amelia Fawcett | F | 67 | 16 years | |
| James H. Stokes | M | 66 |
The University of Texas at Austin
| 7 years |
| M. Connolly | M | 47 | 5 years | |
| Diana Walters | F | 60 |
The University of Texas at Austin
| 5 years |
| Jeffery D. Hildebrand | M | 64 |
The University of Texas at Austin
| 6 years |
| Jaime Sanchez Yarza | M | - | - | |
| Donald T. Nicolaisen | M | 79 | 11 years | |
| Stephen Keith | M | 71 | 8 years | |
| Carroll A. Reddic | M | 58 | 14 years | |
| Lyle A. Hohnke | M | 80 | 3 years | |
| Hutham Olayan | F | 69 | 15 years | |
| Gerard Arpey | M | 65 |
The University of Texas at Austin
| 6 years |
| Philip J. Purcell | M | 80 | 19 years | |
| Patrick Paul Vanek | M | 68 | 5 years | |
| Robert Wood Jones | M | 73 | 32 years | |
| Seth Krauss | M | 53 | 3 years | |
| Lynne Hohlfeld | F | 64 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 3 years |
| Gary G. Lynch | M | 73 | 5 years | |
| Lewis Little | M | 67 |
The University of Texas at Austin
| 6 years |
| David Hung | M | 67 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 5 years |
| Mark T. McLoughlin | M | 68 | 11 years | |
| Howard Davies | M | 73 | - | |
| Charles Phillips | M | 64 | 4 years | |
| James R. McGlynn | M | - |
The University of Texas at Austin
| 7 years |
| Jeff Lucado | M | - |
The University of Texas at Austin
| 6 years |
| Rick S. Kent | M | 74 | 2 years | |
| Brian L. Gerber | M | - |
The University of Texas at Austin
| 6 years |
| Kirk Calhoun | M | 80 | - | |
| Robert L. Hargett | M | - |
The University of Texas at Austin
| 7 years |
| Eileen Murray | F | 66 | 2 years | |
| Gail Maderis | F | 66 |
Opexa Therapeutics, Inc.
Opexa Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Opexa Therapeutics, Inc. engages as a biopharmaceutical company, which develops personalized immunotherapy with the potential to treat major illnesses including multiple sclerosis and other autoimmune diseases. Its product candidates include Tcelna and OPX-212. The company was founded in March 1991 and is headquartered in The Woodlands, TX. | 6 years |
| Michael T. Segrest | M | - |
The University of Texas at Austin
| 6 years |
| Gary W. Parr | M | 67 | 9 years | |
| Fred Coulson | M | - | - | |
| Roy J. Bostock | M | 83 | 8 years | |
| Nelson Haight | M | 59 |
The University of Texas at Austin
| 5 years |
| Alan D. Green | M | 59 |
The University of Texas at Austin
| 4 years |
| Franklin Ruben | M | - |
The University of Texas at Austin
| 7 years |
| Kenneth G. Hawari | M | 65 |
The University of Texas at Austin
| 4 years |
| Karishma Chopra | F | - | 11 years | |
| Jason Gellert | M | - | 5 years | |
| Kay Cuclis | F | - |
The University of Texas at Austin
| 4 years |
| James Head | M | 58 | 13 years | |
| Jim Sherwin | M | - |
The University of Texas at Austin
| 6 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 100 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- David Jorden
- Personal Network
